ATE366584T1 - Verwendung von glp-1 peptiden - Google Patents

Verwendung von glp-1 peptiden

Info

Publication number: ATE366584T1
Authority: AT; Austria
Prior art keywords: glp; peptides; satiety; appetite; analogue
Prior art date: 1996-11-12

Application number

AT05002085T

Other languages

English (en)

Inventor

Liselotte Bjerre Knudsen

Lars Thim

Martin Edward Judge

Jens Juul Holst

Arne Vernon Astrup

Brigitte Schellerup Wulff

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-11-12

Filing date

1997-11-07

Publication date

2007-08-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8102971&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE366584(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-11-07 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

2007-08-15 Application granted granted Critical

2007-08-15 Publication of ATE366584T1 publication Critical patent/ATE366584T1/de

Links

102400000322 Glucagon-like peptide 1 Human genes 0.000 title 1
102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 1
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
235000019789 appetite Nutrition 0.000 abstract 1
230000036528 appetite Effects 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
230000006698 induction Effects 0.000 abstract 1
230000002093 peripheral effect Effects 0.000 abstract 1
230000036186 satiety Effects 0.000 abstract 1
235000019627 satiety Nutrition 0.000 abstract 1
230000001629 suppression Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Zoology (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Child & Adolescent Psychology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

AT05002085T 1996-11-12 1997-11-07 Verwendung von glp-1 peptiden ATE366584T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DK127096		1996-11-12

Publications (1)

Publication Number	Publication Date
ATE366584T1 true ATE366584T1 (de)	2007-08-15

Family

ID=8102971

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT05002085T ATE366584T1 (de)	1996-11-12	1997-11-07	Verwendung von glp-1 peptiden
AT97911155T ATE289517T1 (de)	1996-11-12	1997-11-07	Verwendung von glp-1 peptiden

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT97911155T ATE289517T1 (de)	1996-11-12	1997-11-07	Verwendung von glp-1 peptiden

Country Status (9)

Country	Link
US (5)	US20030232754A1 (de)
EP (2)	EP0941114B1 (de)
JP (1)	JP2001504105A (de)
AT (2)	ATE366584T1 (de)
AU (1)	AU4863797A (de)
DE (2)	DE69737916T2 (de)
ES (2)	ES2290799T3 (de)
WO (1)	WO1998020895A1 (de)
ZA (1)	ZA9710182B (de)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6852690B1 (en)	1995-08-22	2005-02-08	Amylin Pharmaceuticals, Inc.	Method and composition for enhanced parenteral nutrition
UA65549C2 (uk)	1996-11-05	2004-04-15	Елі Ліллі Енд Компані	Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6380357B2 (en)	1997-12-16	2002-04-30	Eli Lilly And Company	Glucagon-like peptide-1 crystals
US6998387B1 (en) *	1998-03-19	2006-02-14	Amylin Pharmaceuticals, Inc.	Human appetite control by glucagon-like peptide receptor binding compounds
US7223727B2 (en)	1998-04-09	2007-05-29	Serono Genetics Institute S.A.	GSSP4 polynucleotides and polypeptides and uses thereof
US6720407B1 (en) *	1998-08-28	2004-04-13	Eli Lilly And Company	Method for administering insulinotropic peptides
US6927214B1 (en)	1999-01-15	2005-08-09	Novo Nordisk A/S	Non-peptide GLP-1 agonists
US6514500B1 (en) *	1999-10-15	2003-02-04	Conjuchem, Inc.	Long lasting synthetic glucagon like peptide {GLP-!}
EP1808438B1 (de)	1999-06-29	2014-10-01	MannKind Corporation	Reinigung und Stabilisierung von Peptiden und Proteinen in pharmazeutischen Wirkstoffen
US9006175B2 (en)	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
JP2003534237A (ja) *	1999-11-03	2003-11-18	ノボノルディスクアクティーゼルスカブ	食欲の抑制又は満腹の惹起のための成長ホルモン又は成長ホルモン分泌促進物質の使用
AU2001256757B2 (en) *	2000-05-16	2006-03-09	Sanwa Kagaku Kenkyusho Co., Ltd.	Agents for preventing or ameliorating insulin resistance and/or obesity
EP1357973B1 (de) *	2001-02-09	2008-08-20	Serono Genetics Institute S.A.	Gssp4-polynukleotide und -polypeptide sowie deren verwendung
CN100350968C (zh)	2001-09-24	2007-11-28	皇家创新有限公司	饮食行为的改进
EP1463751B1 (de)	2001-12-21	2013-05-22	Human Genome Sciences, Inc.	Albuminfusionsproteine
EP1463752A4 (de)	2001-12-21	2005-07-13	Human Genome Sciences Inc	Albuminfusionsproteine
NZ534125A (en)	2002-02-20	2006-11-30	Emisphere Tech Inc	A formulation comprising a GLP-1 compound and a delivery agent
ATE385193T1 (de)	2002-03-20	2008-02-15	Mannkind Corp	Inhalationsgerät
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2005056036A2 (en)	2003-12-09	2005-06-23	Novo Nordisk A/S	Regulation of food preference using glp-1 agonists
US20060286129A1 (en)	2003-12-19	2006-12-21	Emisphere Technologies, Inc.	Oral GLP-1 formulations
CA2554089C (en)	2004-02-09	2013-10-22	Human Genome Sciences, Inc.	Albumin fusion proteins
PL1745078T3 (pl)	2004-04-23	2009-12-31	Conjuchem Biotechnologies Inc	Sposób oczyszczania koniugatów albumin
US8410047B2 (en)	2004-06-11	2013-04-02	Novo Nordisk A/S	Counteracting drug-induced obesity using GLP-1 agonists
KR101273120B1 (ko)	2004-08-20	2013-06-13	맨카인드 코포레이션	다이케토피페라진 합성의 촉매 작용
ES2540886T3 (es)	2004-08-23	2015-07-14	Mannkind Corporation	Sales de dicetopiperazina para la administración de fármacos
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
AU2006265814B2 (en)	2005-06-30	2012-05-10	Ipsen Pharma S.A.S.	GLP-1 pharmaceutical compositions
CN104324366B (zh)	2005-09-14	2016-10-05	曼金德公司	以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法
PL1767545T3 (pl)	2005-09-22	2010-04-30	Biocompatibles Uk Ltd	Polipeptydy fuzyjne GLP-1 (glukagonopodobny peptyd-1) o zwiększonej odporności na peptydazy
US8039432B2 (en)	2005-11-09	2011-10-18	Conjuchem, Llc	Method of treatment of diabetes and/or obesity with reduced nausea side effect
EP2364735A3 (de)	2005-12-16	2012-04-11	Nektar Therapeutics	Verzweigte PEG-Kon jugate von GLP-1
ES2647080T3 (es)	2006-02-22	2017-12-19	Mannkind Corporation	Un método para mejorar las propiedades farmacéuticas de micropartículas que comprenden dicetopiperazina y un agente activo
EP1852108A1 (de)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	Zusammensetzungen von DPP-IV-Inhibitoren
NO347644B1 (no)	2006-05-04	2024-02-12	Boehringer Ingelheim Int	Polymorfer
PE20110235A1 (es)	2006-05-04	2011-04-14	Boehringer Ingelheim Int	Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
DE602006009631D1 (de)	2006-05-10	2009-11-19	Biocompatibles Uk Ltd	GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
AU2007278994B2 (en)	2006-07-24	2013-08-15	Biorexis Pharmaceutical Corporation	Exendin fusion proteins
TWI428346B (zh)	2006-12-13	2014-03-01	Imp Innovations Ltd	新穎化合物及其等對進食行為影響
CN101868476B (zh)	2007-09-05	2015-02-25	诺沃-诺迪斯克有限公司	胰高血糖素样肽-1衍生物及其制药用途
JP2010538049A (ja)	2007-09-05	2010-12-09	ノボ・ノルデイスク・エー／エス	切断型ｇｌｐ−１誘導体及びその治療的使用
EP2214647A2 (de) *	2007-10-24	2010-08-11	MannKind Corporation	Abgabe von wirkstoffen
JP2011500850A (ja) *	2007-10-24	2011-01-06	マンカインドコーポレイション	Ｇｌｐ−１による副作用を防止する方法
US8785396B2 (en)	2007-10-24	2014-07-22	Mannkind Corporation	Method and composition for treating migraines
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
DK2293833T3 (en)	2008-06-13	2016-05-23	Mannkind Corp	DRY POWDER INHALER AND MEDICINAL ADMINISTRATION SYSTEM
CA2728523C (en)	2008-06-20	2020-03-10	Mannkind Corporation	An interactive apparatus and method for real-time profiling of inhalation efforts
KR20200118243A (ko)	2008-08-06	2020-10-14	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
TWI614024B (zh)	2008-08-11	2018-02-11	曼凱公司	超快起作用胰島素之用途
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
EP2216042A1 (de)	2009-02-09	2010-08-11	Ipsen Pharma S.A.S.	GLP1-analoge pharmazeutische Zusammensetzungen
DK2405963T3 (da)	2009-03-11	2013-12-16	Mannkind Corp	Apparat, system og fremgangsmåde til at måle modstand i en inhalator
SG176738A1 (en)	2009-06-12	2012-01-30	Mannkind Corp	Diketopiperazine microparticles with defined specific surface areas
US20120148586A1 (en)	2009-08-27	2012-06-14	Joyce Ching Tsu Chou	Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
EP2496295A1 (de)	2009-11-03	2012-09-12	MannKind Corporation	Vorrichtung und verfahren zur simulation von einatmungsanstrengungen
EA034869B1 (ru)	2009-11-27	2020-03-31	Бёрингер Ингельхайм Интернациональ Гмбх	Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
WO2011138421A1 (en)	2010-05-05	2011-11-10	Boehringer Ingelheim International Gmbh	Combination therapy
RU2571331C1 (ru)	2010-06-21	2015-12-20	Маннкайнд Корпорейшн	Системы и способы доставки сухих порошковых лекарств
CA2803646A1 (en)	2010-07-02	2012-01-05	Angiochem Inc.	Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
US9034883B2 (en)	2010-11-15	2015-05-19	Boehringer Ingelheim International Gmbh	Vasoprotective and cardioprotective antidiabetic therapy
PT2651398T (pt)	2010-12-16	2018-03-09	Novo Nordisk As	Composições sólidas compreendendo um agonista de glp-1 e um sal de ácido n-(8-(2-hidroxibenzoil)amino) caprílico
AU2012236150B2 (en)	2011-04-01	2016-03-31	Mannkind Corporation	Blister package for pharmaceutical cartridges
AU2012241894B2 (en)	2011-04-12	2015-12-03	Novo Nordisk A/S	Double-acylated GLP-1 derivatives
WO2012174472A1 (en)	2011-06-17	2012-12-20	Mannkind Corporation	High capacity diketopiperazine microparticles
BR112014009686A2 (pt)	2011-10-24	2018-08-07	Mannkind Corp	composição analgésica inalável, pó seco e método para tratar dor
US20130172244A1 (en) *	2011-12-29	2013-07-04	Thomas Klein	Subcutaneous therapeutic use of dpp-4 inhibitor
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
HUE042757T2 (hu)	2012-03-22	2019-07-29	Novo Nordisk As	Szállító szert tartalmazó készítmények és elõállításuk
ES2690553T3 (es)	2012-03-22	2018-11-21	Novo Nordisk A/S	Composiciones de péptidos GLP-1 y preparación de estas
JP6224084B2 (ja)	2012-05-14	2017-11-01	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP2863895B1 (de)	2012-06-20	2021-04-14	Novo Nordisk A/S	Tablettenformulierung enthaltend ein peptid und einen adsorptionsvermittler
CN108057154B (zh)	2012-07-12	2021-04-16	曼金德公司	干粉药物输送系统和方法
EP2911690A1 (de)	2012-10-26	2015-09-02	MannKind Corporation	Inhalierbare influenza-impfstoffzusammensetzungen und verfahren
US10421729B2 (en)	2013-03-15	2019-09-24	Mannkind Corporation	Microcrystalline diketopiperazine compositions and methods
TWI638831B (zh)	2013-05-28	2018-10-21	日商武田藥品工業股份有限公司	胜肽化合物
US9925144B2 (en)	2013-07-18	2018-03-27	Mannkind Corporation	Heat-stable dry powder pharmaceutical compositions and methods
CA2920488C (en)	2013-08-05	2022-04-26	Mannkind Corporation	Insufflation apparatus and methods
JP6615109B2 (ja)	2014-02-28	2019-12-04	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｄｐｐ−４阻害薬の医学的使用
WO2015148905A1 (en)	2014-03-28	2015-10-01	Mannkind Corporation	Use of ultrarapid acting insulin
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
JP6995042B2 (ja)	2016-05-24	2022-02-04	武田薬品工業株式会社	ペプチド化合物
EP4233840A3 (de)	2016-06-10	2023-10-18	Boehringer Ingelheim International GmbH	Kombinationen aus linagliptin und metformin
SG11202006595RA (en)	2018-02-02	2020-08-28	Novo Nordisk As	Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
CN113181346A (zh)	2018-03-09	2021-07-30	上海仁会生物制药股份有限公司	用于治疗肥胖和体重管理的glp-1组合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5120712A (en) *	1986-05-05	1992-06-09	The General Hospital Corporation	Insulinotropic hormone
US5118666A (en) *	1986-05-05	1992-06-02	The General Hospital Corporation	Insulinotropic hormone
US5418218A (en) *	1992-07-10	1995-05-23	The University Of Maryland At Baltimore	Histidyl-proline diketopiperazine (cyclo his-pro) a cns-active pharmacologic agent
US5380872A (en) *	1992-07-14	1995-01-10	Glaxo Inc.	Modulators of cholecystokinin
DK1975177T3 (da) *	1996-03-01	2011-07-25	Novo Nordisk As	Appetitundertrykkende peptid, formuleringer dermed og anvendelse deraf
US5912229A (en) *	1996-03-01	1999-06-15	Novo Nordisk Als	Use of a pharmaceutical composition comprising an appetite-suppressing peptide
US7235627B2 (en) *	1996-08-30	2007-06-26	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6458924B2 (en) *	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6268343B1 (en) *	1996-08-30	2001-07-31	Novo Nordisk A/S	Derivatives of GLP-1 analogs
UA65549C2 (uk) *	1996-11-05	2004-04-15	Елі Ліллі Енд Компані	Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
WO1998030231A1 (en) *	1997-01-07	1998-07-16	Amylin Pharmaceuticals, Inc.	Use of exendins and agonists thereof for the reduction of food intake
IL135255A0 (en) *	1998-01-30	2001-05-20	Novo Nordisk As	An injection syringe
US6420137B1 (en) *	1998-11-25	2002-07-16	American Home Products Corporation	Nucleic acid encoding human neurotensin subtype 2 receptor
US6528486B1 (en) *	1999-07-12	2003-03-04	Zealand Pharma A/S	Peptide agonists of GLP-1 activity
US6399089B1 (en) *	2000-05-15	2002-06-04	A. Glenn Braswell	Compositions and methods for regulating metabolism and balancing body weight
US20020187926A1 (en) *	2001-03-07	2002-12-12	Knudsen Liselotte Bjerre	Combined use of derivatives of GLP-1 analogs and PPAR ligands
US7041646B2 (en) *	2001-10-05	2006-05-09	Bayer Pharmaceuticals Corporation	Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists

1997
- 1997-11-07 AT AT05002085T patent/ATE366584T1/de not_active IP Right Cessation
- 1997-11-07 ES ES05002085T patent/ES2290799T3/es not_active Expired - Lifetime
- 1997-11-07 EP EP97911155A patent/EP0941114B1/de not_active Expired - Lifetime
- 1997-11-07 DE DE69737916T patent/DE69737916T2/de not_active Revoked
- 1997-11-07 ES ES97911155T patent/ES2237790T3/es not_active Expired - Lifetime
- 1997-11-07 WO PCT/DK1997/000509 patent/WO1998020895A1/en active IP Right Grant
- 1997-11-07 DE DE69732572T patent/DE69732572T2/de not_active Expired - Lifetime
- 1997-11-07 EP EP05002085A patent/EP1529534B1/de not_active Revoked
- 1997-11-07 JP JP52206198A patent/JP2001504105A/ja not_active Ceased
- 1997-11-07 AU AU48637/97A patent/AU4863797A/en not_active Abandoned
- 1997-11-07 AT AT97911155T patent/ATE289517T1/de not_active IP Right Cessation
- 1997-11-12 ZA ZA9710182A patent/ZA9710182B/xx unknown
2003
- 2003-03-06 US US10/382,438 patent/US20030232754A1/en not_active Abandoned
2007
- 2007-03-05 US US11/714,000 patent/US20070161568A1/en not_active Abandoned
2009
- 2009-02-12 US US12/370,308 patent/US20090149387A1/en not_active Abandoned
2010
- 2010-01-04 US US12/651,685 patent/US20100113363A1/en not_active Abandoned
- 2010-10-15 US US12/905,324 patent/US20110028391A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1529534A2 (de)	2005-05-11
ATE289517T1 (de)	2005-03-15
JP2001504105A (ja)	2001-03-27
EP1529534A3 (de)	2005-06-08
AU4863797A (en)	1998-06-03
DE69732572D1 (de)	2005-03-31
WO1998020895A1 (en)	1998-05-22
EP0941114A1 (de)	1999-09-15
ES2237790T3 (es)	2005-08-01
DE69732572T2 (de)	2005-12-29
US20090149387A1 (en)	2009-06-11
DE69737916T2 (de)	2008-04-03
US20070161568A1 (en)	2007-07-12
DE69737916D1 (de)	2007-08-23
ZA9710182B (en)	1998-05-12
US20100113363A1 (en)	2010-05-06
US20110028391A1 (en)	2011-02-03
EP1529534B1 (de)	2007-07-11
EP0941114B1 (de)	2005-02-23
ES2290799T3 (es)	2008-02-16
US20030232754A1 (en)	2003-12-18

Publication	Publication Date	Title
DE69732572D1 (de)	2005-03-31	Verwendung von glp-1 peptiden
NO940219D0 (no)	1994-01-21	Rekombinante antistoffer for human terapi
ATE306931T1 (de)	2005-11-15	Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
AU8402691A (en)	1992-03-17	Dental curing lamp and apparatus
NO961796L (no)	1996-11-06	Rekombinante fedme (ob) proteiner
DK587589D0 (da)	1989-11-22	Sammensat kompressions- og stoetteforbinding og dens anvendelse samt deri indgaaende adhaesivmateriale
BG100974A (en)	1998-04-30	Vaccines against papillomavirus
BR9607583B1 (pt)	2009-12-01	plasmìdios procarióticos recombinantes.
ATE189480T1 (de)	2000-02-15	Rekombinantes avipoxvirus
AU6428890A (en)	1991-04-18	Therapeutic peptides and proteins
EP0557455A4 (en)	1994-08-24	Recombinant feline coronavirus s proteins
HUT73215A (en)	1996-06-28	Recombinant adenoviruses and use thereof in gene therapy
AU7617791A (en)	1992-11-19	Recombinant immunocastration vaccine
ATE225806T1 (de)	2002-10-15	D-2-alkyltryptophan enthaltende polypeptide mit wachstumhormon freisetzender aktivitaet
DE69123345D1 (de)	1997-01-09	Sequenzielle c-termin degradierung von peptiden und proteinen
GR3036775T3 (en)	2002-01-31	Macroscopically oriented cell adhesion protein for wound treatment.
AU2623088A (en)	1989-11-03	New anti-receptor peptides and therapeutic agents
MX9205978A (es)	1993-04-01	Nuevas proteinas inhibidoras de trombina de garrapatas.
AU3152089A (en)	1989-09-21	Method and composition for ophthalmic anesthesia using rodocaine
EP0351017A3 (en)	1990-05-30	Pharmaceutical composition useful for the treatment of cardiovascular diseases
NZ333652A (en)	2000-07-28	Inhibition of human rotavirus infection using kappa-casein
EE03187B1 (et)	1999-06-15	Pakett hormoonasendusraviks
AU1649592A (en)	1992-12-21	Recombinant immunocastration vaccine and polypeptides useful for same
SE9100284D0 (sv)	1991-01-30	Novel peptide
GB9013872D0 (en)	1990-08-15	Use of protein a and polypeptide components thereof in the treatment of tumours

Legal Events

Date	Code	Title	Description
2008-01-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties